Impact on physical fitness and cognitive ability in school children from southern Côte d'Ivoire after treatment against intestinal helminth infections

Impact on physical fitness and cognitive ability in school children from southern Côte d'Ivoire after treatment against soil-transmitted helminths and schistosomiasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN37143632

Enrollment

300

Registered

2012-11-19

Start date

2012-11-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neglected tropical diseases (soil-transmitted helminth and schistosomiasis infections) and malaria Infections and Infestations Schistosomiasis, unspecified

Interventions

All participants of the study will be treated against soil-transmitted helminths and schistosomiasis with a single dose of albendazole (400 mg) and praziquantel (40 mg/kg), respectively, at baseline,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Primary school child, aged 8-15 years, male or female 2. Written informed consent by a parent/guardian on behalf of the child 3. Submission of 1 urine, 1 stool and 1 finger-prick blood sample at baseline 4. Completion of clinical, anthropometric and haemoglobin measurements at baseline 5. Completion of 20 m shuttle run test at baseline 6. Completion of grip strength test and standing broad jump test at baseline 7. Completion of cognitive testing 8. Absence of difficult health condition (clinical malaria, severe anemia, respiratory disease or other major illnesses) as assessed by a medical doctor at baseline 9. No known or reported drug allergy to albendazole or praziquantel 10. Treatment with albendazole and praziquantel

Exclusion criteria

Exclusion criteria: 1. Children below the age of 8 years or above 15 years 2. No written informed consent 3. No complete set of urine, stool and blood sample submitted at baseline 4. Presence of medical condition that prevents child from completing the physical fitness and strength tests 5. Known or reported drug allergy to albendazole or praziquantel 6. Absence/refusal of albendazole and/or praziquantel treatment 7. Attending other clinical trials during the study period

Design outcomes

Secondary

Measure	Time frame
1. Reduction of infection prevalence and intensity of soil-transmitted helminths and schistosomiasis 2. Differences and changes in disease-related morbidity measures (malnutrition, anemia, organomegaly)	—

Primary

Measure	Time frame
Differences (non-infected vs. infected) and changes (before and after treatment) in physical fitness, strength and cognitive ability	—

Countries

Cote d'Ivoire

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026